PartowKebriaeiMD

Oncology • Houston, TX

Physician

Join to view full profile

Dr. Kebriaei is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kebriaei's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1997 - 2000
McGovern Medical School at UTHealthClass of 1997

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 1998 - 2025
OK State Medical License 2020 - 2021
IL State Medical License 2000 - 2005
American Board of Internal Medicine Hematology

Clinical Trials

Cellular Therapy With Cord Blood Cells Start of enrollment: 2006 Oct 01
Completed
Phase 2
Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma Start of enrollment: 2004 Dec 01
Completed
Phase 2
Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia Start of enrollment: 2005 Jul 01
Completed
Phase 2
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies Start of enrollment: 2011 Jun 20
Completed
Phase 1
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation Start of enrollment: 2009 Oct 01
Completed
Phase 2
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood Start of enrollment: 2011 Dec 01
Completed
Phase 1
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant Start of enrollment: 2014 Mar 06
Completed
Phase 1
CD19-Specific T Cells Post AlloSCT Start of enrollment: 2020 Jun 26
Terminated
Phase 1
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease Start of enrollment: 2021 Feb 17
Recruiting
Early Phase 1
Roles: Principal Investigator, Contact
Long-Term Follow-Up of Recipient of Gene Transfer Research Start of enrollment: 2011 Dec 09
Recruiting
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Transplant in ALL: who, when, and how?
Curtis Marcoux, Partow Kebriaei
Hematology. American Society of Hematology. Education Program. 2024-12-06
1 citations
A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission.
Zaid Abdel Rahman, Tamer Othman, Rima M Saliba, Yenny Alejandra Moreno Vanegas, Razan Mohty
Transplantation and Cellular Therapy. 2024-12-01
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia...
Farhad Ravandi, Jayastu Senapati, Nitin Jain, Nicholas J Short, Tapan Kadia
Leukemia. 2024-12-01

Journal Articles

Pilot Study Using Post-Transplant Cyclophosphamide (PTCy), Tacrolimus and Mycophenolate GVHD Prophylaxis for Older Patients Receiving 10/10 HLA-Matched Unrelated Donor...
Uday R Popat, Amin Alousi, Issa F Khouri, Muzaffar Qazilbash, Richard E Champlin, Partow Kebriaei, Simrit Parmar, Chitra Hosing, Nature
Impact of a Novel Prognostic Model, Hematopoietic Cell Transplant-Composite Risk (HCT-CR), on Allogeneic Transplant Outcomes in Patients with Acute Myeloid Leukemia an...
Uday Popat, Chitra M Hosing, Issa Khouri, Richard Champlin, Simrit Parmar, Partow Kebriaei, Borje S Andersson, Qaiser Bashir, Amin Alousi, Nature
Management Guidelines for Paediatric Patients Receiving Chimeric Antigen Receptor T Cell Therapy
Kris M Mahadeo, Julie C Fitzgerald, Marie E Steiner, Partow Kebriaei, Katayoun Rezvani, Ira M Cheifetz, John M Slopis, Paul L Martin, Sattva S Neelapu, Agne Tarasevici..., Nature

Abstracts/Posters

Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receivi...
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopo...
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Incidence and Cost of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with and without Multi-Organ Dysfunction: Analysis of the Premier Healthcare Database
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Do...
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disea...
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Sinusoidal Obstructive Syndrome Among Pediatric and Adolescent and Young Adult Patients: Analysis of Pediatric EBMT Diagnostic and Severity Criteria at MD Anderson
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pt...
Partow Kebriaei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Hematopoietic Cell Transplant -Composite Risk (HCT-CR) - a Novel Prognostic Model to Predict Transplant Outcomes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A phase 1 multicenter study evaluating the safety and efficacy of MHC class II-restricted MAGE-A3/A6 T-cell receptor engineered T cells (KITE-718) in patients with adv...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all